GLP-1 Non-Responders: Why a Microdose May Not Move the Scale and What the Early-Response Data Shows

The worry usually arrives around the second or third month. A friend on the same medicine has lost a visible amount, the appetite change feels mild, and the scale has barely shifted. Being a "non-responder" starts to sound like a personal diagnosis, and people start wondering whether they should take more.

This article covers how researchers define low response, what the early-response analyses found, who tends to lose less, and what to raise with a prescriber. Almost all of the data comes from standard doses. We say so wherever that limits the conclusion, because a microdose is a different starting point from the doses these studies tested.

What counts as a GLP-1 non-responder?

The papers cited here generally treat less than 5% weight loss as low response, judged at a fixed time point. That threshold was a coprimary endpoint in both STEP 1 (Wilding and colleagues, New England Journal of Medicine, 2021) and SURMOUNT-1 (Jastreboff and colleagues, New England Journal of Medicine, 2022). The label is a research tool. It says nothing about why a given person missed the line.

Read the placebo bars as well. About a third of the placebo group in these trials without diabetes passed 5%, with a lifestyle program behind them. So 5% does not separate drug effect from everything else, and missing it does not isolate the drug as the problem.

A flat scale after real loss is a different question. Stopping after losing weight is a plateau, covered in our guide to why GLP-1 weight loss stalls. Fading appetite effects over time belong to the separate question of tolerance and receptor desensitization.

Does a microdose make low response more likely?

Probably, in the plain sense that less drug produced less average weight loss in the one trial that tested low doses in adults without diabetes. O'Neil and colleagues randomized 957 adults to once-daily semaglutide from 0.05 mg to 0.4 mg, liraglutide 3.0 mg or placebo (The Lancet, 2018). Doses went up every 4 weeks, and weight was measured at week 52.

Even the smallest arm beat placebo, at 6.0% against 2.3%. The trial has limits for anyone on a weekly microdose, though. These were daily injections held for most of a year, so the arms should not be converted into weekly equivalents and read as a microdose result. Our article on low-dose semaglutide, dose by dose goes further into these arms.

Observational data suggests that lower doses can go a long way for some people, with heavy caveats. Seier and colleagues followed 2694 people in a Danish app-based program with personalized dosing and behavioral therapy (Diabetes, Obesity and Metabolism, 2025). Mean weight loss at week 64 was 16.7% on a mean of 1.08 mg/week, and 98% reached at least 5%. Only 465 participants remained at that point, there was no control group, and some authors had ties to the company. People who were not losing weight may well have been the ones who left. Doses of 1.08 mg/week are also well above what most people mean by a microdose.

Can slow starters still catch up?

Yes, at standard doses, many did, although they tended to finish with less total loss than fast starters. Kokkinos and colleagues split 2384 tirzepatide participants from SURMOUNT-1 and SURMOUNT-2 by whether they had lost at least 5% by week 8 (Diabetes, Obesity and Metabolism, 2026). Early responders were 62.1% of SURMOUNT-1 and 40.6% of SURMOUNT-2.

The later group's results are the useful part for anyone who feels behind. Most of them still crossed 5% by week 72, and many passed 10%. The analysis is post hoc and written largely by Eli Lilly employees, and it used an efficacy estimand, which reflects people who stayed on treatment.

STEP 4 points the same way for semaglutide. In a conference abstract, Mosenzon and colleagues reported that 88.0% of those randomized to continue semaglutide had reached 5% by week 20 (Journal of the Endocrine Society, 2021). Everyone took semaglutide up to 2.4 mg during that period, and the trial then randomized participants to continue or switch to placebo, which allows a rare direct comparison among slow starters.

Being on track at week 20 told researchers a lot, with a positive predictive value of 96.4% for reaching 5% at week 68. Being behind told them much less, with a negative predictive value of 42.9%. Put plainly, a slow start in this trial was a poor basis for writing someone off.

A real-world tirzepatide study by Angelopoulos and colleagues adds a later checkpoint (Obesity Pillars, 2026). Among 179 patients measured at 6 and 12 months, 70.4% lost more than 2% further in the second half of the year, and 10.1% regained more than 2%. The mean dose at 12 months was 9.71 mg, again far from microdose territory.

Who tends to lose less on a GLP-1?

Type 2 diabetes is the most consistent predictor of smaller weight loss across the trials we reviewed. The gap shows up at every comparable dose, in STEP 2 (Davies and colleagues, The Lancet, 2021) and SURMOUNT-2 (Garvey and colleagues, The Lancet, 2023). These are comparisons across separate trials with different participants, so they show a pattern and do not measure an exact gap.

Sex comes next. Tzoulis summarizes semaglutide studies in which women lost more than men by a mean 6% (Frontiers in Endocrinology, 2026), and early responders in the tirzepatide analysis were more likely to be female. A man comparing his progress with a woman's on the same dose may be comparing against a different average.

Metabolic conditions matter too. Lu and colleagues ran a meta-regression of 32 trials and 40,408 participants (Clinical Obesity, 2026). Type 2 diabetes, obstructive sleep apnea and fatty liver disease each went with a smaller response, while tirzepatide and treatment lasting at least 72 weeks went with a larger one. Readers with blood sugar concerns can find more in our guide to insulin sensitivity on a GLP-1 microdose.

Some predictors remain disputed. The systematic review by Gaskin and Chami (Obesity Reviews, 2026) lists higher baseline BMI and older age among factors linked to poorer response, while Tzoulis finds no clear association for either with semaglutide. Treat age and starting weight as open questions.

Is GLP-1 non-response genetic?

Partly, it seems, but the known genetic effect is small. Su and colleagues at 23andMe ran a genome-wide study of self-reported weight loss and side effects in 27,885 people (Nature, 2026). A missense variant in the GLP1R gene was tied to about 0.76 kg of extra weight loss per copy. All authors are current or former 23andMe employees, and the weight data was self-reported.

That finding helps explain variation between people, but it cannot account for someone losing nothing. Tzoulis describes the impact of genetic variants on semaglutide response as incompletely understood and limited so far to modest effects. The same review calls data on the "hungry gut" phenotype preliminary. No test we found has been validated to tell you in advance whether a microdose will work.

Do side effects show that a GLP-1 is working?

No. Weight loss on semaglutide 2.4 mg was largely independent of stomach side effects. Wharton and colleagues pooled STEP 1 to 3, including 2117 people on the drug (Diabetes, Obesity and Metabolism, 2022). Mean weight loss was 9.6%-17.1% without gastrointestinal events and 11.4%-17.7% with them, and less than 1 percentage point of the drug's added effect was explained by those events.

The tirzepatide analysis fits this picture: the pattern, severity and timing of gastrointestinal events were similar in fast and slow starters. A quiet stomach on a low dose tells you little about the eventual result, and nausea is not a sign to chase. Our guide to managing nausea on a microdose covers the symptom itself.

What should you check before calling a microdose a failure?

Start with the dose you actually received and how consistently you took it, because neither is guaranteed. Gaskin and Chami found adherence strongly associated with treatment success. For a compounded vial, FDA has reported patients drawing up the wrong amount, in some cases five to 20 times the intended dose (FDA alert, 2024). That alert concerns overdoses, but it shows how easily vial measuring can go wrong. Our guide to storage and dosing accuracy walks through the details.

Then bring these questions to a prescriber:

• •How long have I been on this exact dose, and how many doses have I missed?
• •Could diabetes, insulin resistance, sleep apnea or fatty liver be affecting my result, and have they been checked?
• •Could another medicine I take be working against weight loss?
• •Is the scale the right measure for my goal, or should we track waist, labs or body composition as well?
• •If a change is warranted, what are the options: more time, a higher dose or a different drug?

Higher doses do produce more on average. Tzoulis reports that semaglutide 7.2 mg beat 2.4 mg by a mean 3%, and Lu and colleagues found larger effects with tirzepatide. Neither result tests a person who failed a low dose, and we found no trial of what to do next in that situation. Our articles on switching from semaglutide to tirzepatide and tracking body composition can help you prepare for that conversation.

Frequently asked questions

Clinical references

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021. doi:10.1056/NEJMoa2032183
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022. doi:10.1056/NEJMoa2206038
3. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021. doi:10.1016/S0140-6736(21)00213-0
4. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. The Lancet. 2023. doi:10.1016/S0140-6736(23)01200-X
5. O'Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet. 2018. doi:10.1016/S0140-6736(18)31773-2
6. Kokkinos A, Thethi T, Lee CJ, et al. Tirzepatide Efficacy and Tolerability According to Early Weight Response: A Post Hoc Analysis of the SURMOUNT-1 and SURMOUNT-2 Trials. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71009
7. Mosenzon O, Garvey WT, Hesse D, et al. Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4). Journal of the Endocrine Society. 2021. Conference abstract. doi:10.1210/jendso/bvab048.013
8. Angelopoulos N, Fousteris E, Zianni D, et al. 12-month weight-loss trajectories and predictors of response to tirzepatide under individualized dosing: A multicenter real-world study. Obesity Pillars. 2026. doi:10.1016/j.obpill.2026.100344
9. Seier S, Stamp-Larsen K, Jensen SBK, et al. Treat to target in weight management with semaglutide: Real-world evidence from an eHealth clinic. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70096
10. Gaskin PS, Chami PS. Low Weight Loss Response to Incretin Analogs: A Systematic Review. Obesity Reviews. 2026. doi:10.1111/obr.70145
11. Lu D, Li N, Yuan Z, et al. Weight Reduction Heterogenicity and Mediators of GLP-1RAs and Dual Agonists for Individuals With Obesity: A Meta-Analysis. Clinical Obesity. 2026. doi:10.1111/cob.70112
12. Tzoulis P. Predictors of treatment response to semaglutide for weight management. Frontiers in Endocrinology. 2026. doi:10.3389/fendo.2026.1893511
13. Su QJ, Ashenhurst JR, Xu W, et al. Genetic predictors of GLP1 receptor agonist weight loss and side effects. Nature. 2026. doi:10.1038/s41586-026-10330-z
14. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes, Obesity and Metabolism. 2022. doi:10.1111/dom.14551
15. US Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. 2024. fda.gov